TABLE 2.
Clinical covariates of the training and validation cohorts.
| Characteristic | Training cohort (n = 175) | Validation cohort GSE (n = 63) |
|---|---|---|
| Sex | ||
| Female | 74 (42%) | — |
| Male | 88 (51%) | — |
| Unknown | 13 (7%) | |
| Age (years) | ||
| ≤60 | 52 (30%) | — |
| >60 | 110 (63%) | — |
| Unknown | 13 (7%) | |
| Grade | ||
| High | 25 (14%) | — |
| Moderate | 88 (51%) | — |
| Poor | 49 (28%) | — |
| Unknown | 13 (7%) | |
| Stage | ||
| I | 16 (9%) | 13 (21%) |
| II | 139 (80%) | 50 (79%) |
| III | 3 (2%) | — |
| IV | 4 (2%) | — |
| Unknown | 13 (7%) | |
| T-stage | ||
| 1 | 5 (3%) | — |
| 2 | 20 (11%) | — |
| 3 | 134 (77%) | — |
| 4 | 3 (2%) | — |
| Unknown | 13 (7%) | |
| N-stage | ||
| 0 | 45 (26%) | — |
| 1 | 117 (67%) | — |
| Unknown | 13 (7%) | |
| Metabolic risk score | ||
| High | 85 (50%) | 33 (52%) |
| Low | 86 (50%) | 30 (48%) |
| Survival | ||
| Alive | 84 (48%) | 21 (33%) |